Dr. Reddys Laboratories Clarifies Semaglutide Injection Status with Health Canada
Dr Reddys Laboratories Ltd provided an update on April 24, 2026, confirming its progress regarding the Semaglutide Injection. The clarification addressed a news item published on April 23, 2026, concerning the status of the product for regulatory approval.The company confirmed that the report suggesting that Dr. Reddy's Laboratories is still awaiting approval for the Semaglutide Injection from Health Canada is accurate.
In terms of regulatory milestones, Dr Reddys Laboratories reported that it received the Drug Identification Numbers (DINs) for the Semaglutide Injection from Health Canada on April 22, 2026.
The company stated that it continues to engage constructively with the regulatory authority and remains committed to bringing the product to the Canadian market once approval is secured.
DRREDDY Stock Price Movement
As of 9:35 AM, shares of Dr. Reddy's Laboratories Limited are slipping by 0.63% in live trading, currently at ₹1322.6. The stock trades on a high volume of 1.33 million shares, suggesting ongoing profit-taking as the market moves through the morning session.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.